Anika Therapeutics (NASDAQ: ANIK) net income
Anika Therapeutics reported a net loss of $10.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $56.4m. Earnings per share were −$0.76.
Anika Therapeutics's best year of the last 10 was fiscal 2016. The biggest drop was in fiscal 2018, −41.2%. It reported a loss in 5 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$10.9m | — | −9.6% | −$0.76 |
| 2024 | −$56.4m | — | −47.0% | −$3.83 |
| 2023 | −$82.7m | — | −68.4% | −$5.64 |
| 2022 | −$14.9m | −459.4% | −13.1% | −$1.02 |
| 2021 | $4.1m | — | 2.8% | $0.29 |
| 2020 | −$24.0m | −188.2% | −18.4% | −$1.69 |
| 2019 | $27.2m | +45.2% | 23.7% | $1.93 |
| 2018 | $18.7m | −41.2% | 17.7% | $1.30 |
| 2017 | $31.8m | −2.2% | 28.1% | $2.18 |
| 2016 | $32.5m | — | 31.5% | $2.22 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Anika Therapeutics net income compared with its sector
By net income for its latest fiscal year, Anika Therapeutics ranks 192nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Anika Therapeutics, −9.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 190th | Century Therapeutics | −$9.6m | −8.8% |
| 191st | Fennec Pharmaceuticals | −$9.7m | −21.8% |
| 192nd | Anika Therapeutics | −$10.9m | −9.6% |
| 193rd | AtriCure | −$11.4m | −2.1% |
| 194th | AirSculpt Technologies | −$11.7m | −7.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Anika Therapeutics
- How much did Anika Therapeutics earn in fiscal 2025?
- Anika Therapeutics reported a net loss of $10.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $56.4m.
- What are the earnings per share of Anika Therapeutics?
- They were −$0.76 in fiscal 2025, compared with −$3.83 in fiscal 2024.
- What was the most profitable year for Anika Therapeutics?
- Of its last 10 fiscal years, fiscal 2016, with $32.5m.
- Where does Anika Therapeutics rank in its sector by net income?
- It ranks 192nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Anika Therapeutics come from?
- From the annual report (Form 10-K) that Anika Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Anika Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anika Therapeutics: the Anika Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.